Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis

De Meester, 1999, CD26, let it cut or cut it down, Immunol Today, 20, 367, 10.1016/S0167-5699(99)01486-3 Mentlein, 1999, Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides, Regul Pept, 85, 9, 10.1016/S0167-0115(99)00089-0 Bluel, 1996, A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1), J Exp Med, 184, 1101, 10.1084/jem.184.3.1101 Proost, 1998, Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha, FEBS Lett, 432, 73, 10.1016/S0014-5793(98)00830-8 Morimoto, 1998, The structure and function of CD26 in the T-cell immune response, Immunol Rev, 161, 55, 10.1111/j.1600-065X.1998.tb01571.x Reinhold, 2002, The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity, Biol Chem, 383, 1133, 10.1515/BC.2002.123 Dang, 1990, Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways, J Immunol, 144, 4092, 10.4049/jimmunol.144.11.4092 Dong, 1997, Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation, J Immunol, 159, 6070, 10.4049/jimmunol.159.12.6070 Ishii, 2001, CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO, Proc Natl Acad Sci USA, 98, 12138, 10.1073/pnas.211439098 Firestein, 2003, Evolving concepts of rheumatoid arthritis, Nature, 423, 356, 10.1038/nature01661 Muscat, 1994, Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients, Clin Exp Immunol, 98, 252, 10.1111/j.1365-2249.1994.tb06134.x Gerli, 1996, CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis, Clin Immunol Immunopathol, 80, 31, 10.1006/clin.1996.0091 Mizokami, 1996, Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis, J Rheumatol, 23, 2022 Hagihara, 1987, Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis, Clin Chem, 33, 1463, 10.1093/clinchem/33.8.1463 Cordero, 2001, Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis, Rheumatol Int, 21, 69, 10.1007/s002960100134 Kamori, 1991, Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis, Biochem Med Metab Biol, 45, 154, 10.1016/0885-4505(91)90016-E Fujita, 1992, The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen, Biochem Med Metab Biol, 48, 227, 10.1016/0885-4505(92)90069-B Tanaka, 1998, Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225, Immunopharmacology, 40, 21, 10.1016/S0162-3109(98)00014-9 Tanaka, 1997, Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV, Int J Immunopharmacol, 19, 15, 10.1016/S0192-0561(97)00004-0 Williams, 2003, Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis, Clin Exp Immunol, 131, 68, 10.1046/j.1365-2249.2003.02020.x Poole, 1999, An introduction to the pathophysiology of osteoarthritis, Front Biosci, 4, D662, 10.2741/Poole Marguet, 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26, Proc Natl Acad Sci USA, 97, 6874, 10.1073/pnas.120069197 Busso, 1998, Exacerbation of antigen-induced arthritis in urokinase-deficient mice, J Clin Invest, 102, 41, 10.1172/JCI2312 Marty, 2001, Amelioration of collagen-induced arthritis by thrombin inhibition, J Clin Invest, 107, 631, 10.1172/JCI11064 Scharpe, 1988, Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine, Clin Chem, 34, 2299, 10.1093/clinchem/34.11.2299 Kobayashi, 2002, Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus, J Rheumatol, 29, 1858 Hildebrandt, 2001, Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease, Scand J Gastroenterol, 36, 1067, 10.1080/003655201750422675 Cuchacovich, 2001, Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases, Clin Exp Rheumatol, 19, 673 Rose, 2002, T-cell immune parameters and depression in patients with Crohn's disease, J Clin Gastroenterol, 34, 40, 10.1097/00004836-200201000-00008 Steinbrecher, 2000, Dipeptidyl peptidase IV in inflammatory CNS disease, Adv Exp Med Biol, 477, 145, 10.1007/0-306-46826-3_16 Steinbrecher, 2001, Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo, J Immunol, 166, 2041, 10.4049/jimmunol.166.3.2041 Preller VBS, Wrenger S, Gerber A, Marguet D, Schraven B, Reinhold D: Enhanced Severity of Experimental Autoimmune Encephalomyelitis and Decreased TGF-β1 Plasma Levels in CD26−/− Mice. Presented at the 34th Annual Meeting of the German Society of Immunology, Berlin, 2003 Kubota, 1992, Involvement of dipeptidyl peptidase IV in an in vivo immune response, Clin Exp Immunol, 89, 192, 10.1111/j.1365-2249.1992.tb06931.x Leiting BNE, Biftu T, Edmonson S, Ok H, Weber A, Zaller D, Thornberry NA: Inhibition of Dipeptidyl Peptidase IV Does Not Attenuate T Cell Activation in Vitro. Presented at the American Diabetes Association-64th Annual Scientific Sessions, Orlando, 2004 Yan, 2003, Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen, Eur J Immunol, 33, 1519, 10.1002/eji.200323469 Coburn, 1994, In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV, Cell Immunol, 158, 269, 10.1006/cimm.1994.1275 Nanki, 2000, Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium, J Immunol, 165, 6590, 10.4049/jimmunol.165.11.6590 Buckley, 2000, Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium, J Immunol, 165, 3423, 10.4049/jimmunol.165.6.3423 Matthys, 2001, AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice, J Immunol, 167, 4686, 10.4049/jimmunol.167.8.4686 Blades, 2002, Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice, Arthritis Rheum, 46, 824, 10.1002/art.10102 Nanki, 2001, Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis, J Immunol, 167, 5381, 10.4049/jimmunol.167.9.5381 De La Luz Sierra, 2004, Differential processing of stromal-derived factor-1 {alpha} and {beta} explains functional diversity, Blood, 103, 2452, 10.1182/blood-2003-08-2857